Curis Raises $80.8 Million for Emavusertib Development in Private Placement Financing

Curis Secures $80.8 Million in Private Placement to Advance Emavusertib Development

Curis, Inc., a biotechnology company focused on innovative cancer therapies, successfully closes a private placement financing that raises up to $80.8 million, with initial proceeds estimated at $20.2 million. This significant financial boost will support the ongoing development of emavusertib (CA-4948), a small molecule inhibitor targeting IRAK4 and FLT3, which is currently undergoing various clinical trials. The financing is backed by prominent investors, including Nantahala Capital, Stonepine Capital Management, and Pointillist Partners, along with participation from existing institutional investors and members of Curis's management and board. Laidlaw & Company (UK) Ltd. acted as the sole placement agent for this transaction, which represents a pivotal moment for Curis as it seeks to advance its clinical research and potential market offerings.

Emavusertib is pivotal to Curis’s strategic vision, particularly in the realm of hematologic malignancies. The drug is being evaluated in a Phase 1/2 study, where it is administered alongside the BTK inhibitor ibrutinib for patients suffering from relapsed or refractory primary central nervous system lymphoma (PCNSL). This combination therapy aims to improve treatment outcomes for a patient population that currently has limited options. Moreover, emavusertib is also being tested in a Phase 2 study for Chronic Lymphocytic Leukemia (CLL), reinforcing Curis’s commitment to addressing urgent medical needs in blood cancers. The company has previously explored emavusertib's efficacy in acute myeloid leukemia (AML) and is determined to further investigate both monotherapy and combination therapy avenues.

Curis’s regulatory achievements bolster the significance of emavusertib in its pipeline. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML, and myelodysplastic syndromes (MDS), as well as recognition from the European Commission for PCNSL. These designations not only highlight the drug's potential but also provide Curis with incentives to expedite development. Furthermore, Curis maintains an exclusive license for emavusertib through its collaboration with Aurigene Discovery Technologies Limited, established in 2015, which enhances its capacity to innovate and deliver transformative therapies in oncology.

In parallel with its clinical advancements, Curis continues to strengthen its financial foundation, which is crucial for sustaining its research and development initiatives. The recent private placement not only provides immediate capital but also reflects growing confidence among investors in Curis's strategic direction and the therapeutic potential of emavusertib. As the company moves forward, it remains dedicated to improving treatment landscape for patients facing challenging malignancies.